Nurix Therapeutics
NRIX
113 hedge funds and large institutions have $1.18B invested in Nurix Therapeutics in 2021 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 15 closing their positions.
1,469% more call options, than puts
Call options by funds: $204K | Put options by funds: $13K
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
13% more capital invested
Capital invested by funds: $1.05B → $1.18B (+$135M)
10% more funds holding
Funds holding: 103 → 113 (+10)
3% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 32
0.25% less ownership
Funds ownership: 89.11% → 88.86% (-0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.8M |
| 3 |
BlackRock
New York
|
+$12.3M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$9.39M |
| 5 |
O
OrbiMed
New York
|
+$8.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$30.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$26M |
| 3 |
Morgan Stanley
New York
|
-$9.37M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.98M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
C
126
Chescapmanager
Baltimore,
Maryland
| – | -$197K | -7,442 | Closed |
|
127
Russell Investments Group
London,
United Kingdom
| – | -$152K | -5,749 | Closed |
|
|
PHK
128
Point72 Hong Kong
Hong Kong
| – | -$3K | -116 | Closed |
|
NRIX Hedge Fund Activity: Q3 2021 in Review
113 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2021, worth a combined $1.18B — up 13% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new NRIX positions and 15 closed out — a net gain of 11 holders — while 33 added to existing stakes and 32 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $20.6M. The largest seller was TRV GP III, cutting an estimated $30.9M.
- 113 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2021, up from 103 in Q2 2021.
- Funds reported $1.18B of Nurix Therapeutics stock for Q3 2021, up 13% quarter-over-quarter.
- 26 funds opened new Nurix Therapeutics positions in Q3 2021 and 15 closed out, a net change of +11 holders.
- The largest Nurix Therapeutics buyer in Q3 2021 was T. Rowe Price Associates, an estimated $20.6M added.
- The largest Nurix Therapeutics seller in Q3 2021 was TRV GP III, an estimated $30.9M sold.
Based on aggregated 13F filings for Q3 2021.